Abstract: Objective The aim of this study was to observe the clinical efficacy of dexmedetomidine and sevoflurane combination anesthesia in patients with primary liver cancer (PLC) undergoing hepatectomy. Methods 57 patients with PLC were enrolled in our hospital between January 2019 and December 2022, and were randomly divided into control (n=28) and observation group (n=29) during hepatectomy, receiving sevoflurane anesthesia or dexmedetomidine and sevoflurane combination anesthesia, respectively. The heart rate (HR) and mean arterial pressure (MAP) were routinely monitored before anesthesia (T0), immediately after surgery (T1), 12 h after surgery (T2) and 24 h after surgery (T3). The pain was evaluated by visual analogue scale (VAS), and serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), cortisol (Cor) and adrenocorticotropic hormone (ACTH) levels were detected by ELISA. Results At T0, T1, T2 and T3, there was no significant differences as respect to HR or MAP between the two groups (P>0.05); at T1, T2 and T3, the VAS scores in combination group were (2.1±0.5), (1.6±0.4) and (1.1±0.2), all significantly lower than in the control group; at T0, serum IL-6, TNF-α, Cor and ACTH levels in the combination group were (5.2±1.1)ng/L, (26.9±4.3)μg/L, (185.6±28.4)mmol/L and (10.6±2.1)pmol/L, not significantly different compared to in the control (P>0.05), while at T3, serum IL-6, TNF-α, Cor and ACTH levels were (9.7±2.6)ng/L, (31.3±4.8)μg/L, (219.7±32.5)mmol/L and (14.8±3.5) pmol/L, all significantly lower than in the control group. Conclusion The dexmedetomidine and sevoflurane combination anesthesia in patients with PLC during hepatectomy could alleviate perioperative pain and relieve perioperative body inflammatory and oxidative stress reactions, which is worthy of further clinical investigation.

Key words: Hepatoma, Hepatectomy, Dexmedetomidine, Sevoflurane, Anesthesia